Foundation Fighting Blindness - jCyte announced that its emerging cellular therapy for people with retinitis pigmentosa (RP) and related diseases has performed encouragingly in a Phase 2b clinical trial. The treatment is
Stem/progenitor cell-based transplantation for retinal degeneration: a review of clinical trials | Cell Death & Disease
Stem cell therapy for retinitis pigmentosa found safe, well-tolerated in first-stage clinical trial | UCI News | UCI
ARVO 2018: Dr. Henry Klassen Provides Update on jCyte Stem Cell Trials
ReNeuron Group - Exploiting the potential of cell therapy | Edison
Clinical Trials and Natural History Studies for Usher Syndrome
Phase 2b Clinical Study of Safety and Efficacy of Intravitreal Injection of Retinal Progenitor Cells (jCell) for Treatment of Retinitis Pigmentosa | California's Stem Cell Agency
Study outlines use of intravitreal injection of allogeneic human retinal progenitor cells to treat RP
jCyte Inc. Announces Promising Results In Retinitis Pigmentosa | The Optical Journal
jCyte starts second phase of stem cell clinical trial targeting vision loss | The Stem Cellar
JCyte Licenses Ex-US Rights to Retinitis Pigmentosa Cell Therapy to Santen for $252 Million - Global Genes
jCyte Inc. Announces Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting | Business Wire
Rebecca Kammer - Vice President of Clinical Operations - jCyte, Inc. | LinkedIn
Santen Pharmaceutical and jCyte Enter Agreement for jCell Therapy for Retinitis Pigmentosa | OphthalmologyWeb: The Ultimate Online Resource for Ophthalmologists
jCyte Inc. Announces Promising Phase 2b Results of jCell Therapy in Retinitis Pigmentosa | Business Wire
UCI receives record $592 million in research funding for fiscal 2020-21 | UCI News | UCI
jCyte Shares Encouraging Update on Clinical Trial for Retinitis Pigmentosa | The Stem Cellar
Clinical Trials and Natural History Studies for Usher Syndrome
jCyte starts second phase of stem cell clinical trial targeting vision loss | The Stem Cellar
Phase 2b Clinical Study of Safety and Efficacy of Intravitreal Injection of Retinal Progenitor Cells (jCell) for Treatment of Retinitis Pigmentosa | California's Stem Cell Agency
Powered by CIRM Grant, jCyte Launches New Clinical Trial for RP - Global Genes
Hardy AIM 🎯 on Twitter: "#RENE 🧬 What is a PSC? A Pluripotent Stem Cell Pluripotent Stem Cells hailed a 🔥“big revolution”🔥 for the advancement of cell Therapy 🔥”Miraculous Cells”🔥 Is quite
jCell Therapy | Retinitis Pigmentosa | Degenerative Retinal Disorders | jCyte Inc.
jCyte Announces Promising Phase IIb Results for Allogeneic Retinal Stem Cell Therapy | BioSpace
